The phytonutrient ursolic acid (UA), present in apples, rosemary, and other plant sources, has anti-cancer properties in a number of systems, including skin cancers. 
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The phytonutrient ursolic acid (UA), present in apples, rosemary, and other plant sources, has anti-cancer properties in a number of systems, including skin cancers.
However, few reports have examined upstream mechanisms by which UA may prevent or treat cancer. Recent reports have indicated UA induces death of cancer cell lines via AMP-activated protein kinase (AMPK), an energy-sensing kinase which possesses both pro-metabolic and anti-cancer effects. Other studies have shown UA activates peroxisome proliferator activated receptor α (PPARα) and the glucocorticoid receptor (GR). Here, we found the cytotoxic effect of UA in skin carcinoma cells required AMPK activation. In addition, two inhibitors of PPARα partially reversed the cytotoxic effects of UA, suggesting its effects are at least partially mediated through this receptor.
Finally, inhibition of the GR did not reverse the effects of UA nor did this compound bind the GR under the conditions of experiments performed. Overall, studies elucidating the anti-cancer effects of UA may allow for the development of more potent analogues utilizing similar mechanisms. These studies may also reveal the mediators of any possible side effects or resistance mechanisms to UA therapy.
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| INTRODUCTION
The natural phytonutrient ursolic acid (UA) has been shown to have both anti-cancer [1] [2] [3] [4] [5] and anti-diabetic 6, 7 effects in a variety of in vitro and in vivo systems. A number of studies indicated UA activates the energy sensor AMP-activated protein kinase (AMPK), 6, 8, 9 which has both anti-cancer and anti-diabetic properties. AMPK is activated by both exercise 10, 11 and calorie restriction. 12, 13 These lifestyle factors induce a negative energy balance, and the resulting increases in the AMP/ATP ratio allosterically interact with and allow activation of AMPK via phosphorylation at threonine 172 (Thr172) by upstream kinases such as LKB1 and CAMKKβ. 14, 15 Activated AMPK stimulates catabolic processes such as fat oxidation and glucose uptake and inhibits anabolic processes such as fatty acid synthesis and gluconeogenesis to restore ATP levels. 16, 17 AMPK also has anti-tumor properties. In this regard, AMPK loss leads to increased tumor formation in lymphoma-susceptible mice.
18
LKB1, the upstream kinase of AMPK, also functions as a tumor suppressor. 19 In addition, recent studies have shown the cytotoxic effects of UA against cancer cells are mediated by AMPK. The AMPK inhibitor Compound C decreased UA-mediated pro-apoptotic signaling in liver cancer cells. 8 Another report found UA-induced apoptosis of bladder cancer cells was suppressed by knockdown of AMPK. 9 In addition, inhibitory phosphorylation of AMPK was shown to increase during progression to human SCC, 20 suggesting a potential role of AMPK as a suppressor of skin carcinoma formation or viability. These studies further suggest that the effects of UA against skin tumor growth in vivo 3 may be mediated, at least in part, by AMPK activation.
Despite many reports demonstrating the anti-cancer effects of UA, very few studies have attempted to determine which upstream proximal receptor(s) contribute to these effects. The peroxisome proliferator activated receptor α (PPARα) is primarily expressed in the liver, kidney, skeletal muscle, and heart and is important for lipid homeostasis and may have anti-inflammatory properties. 21 Ligands for
PPARα have been shown to inhibit skin tumorigenesis in vivo 22 and activate AMPK. 23 Also, synthesized derivatives of a UA isomer bound different PPARs 24 and resulted in downstream anti-inflammatory and anti-skin tumor effects. 25 In addition, UA enhanced PPARα promoterbinding and overall transcriptional activity in HepG2 liver cancer cells.
However, UA did not directly bind PPARα. 26 Overall, these studies suggest that the anti-cancer effect of UA may also involve activation of PPARα through a mechanism independent of ligand binding.
Another potential candidate receptor for UA is the glucocorticoid receptor (GR), which has anti-inflammatory properties both through transrepressive interactions with pro-inflammatory transcription factors and through transactivation of promoters leading to synthesis of anti-inflammatory proteins. 27 The structure of UA strongly resembles that of typical glucocorticoids, which also inhibit skin tumor promotion. 28, 29 UA also enhanced GR nuclear translocation, 30, 31 and UA-mediated decreases in MMP-9 expression are reversed by GR antagonist RU486 in fibrosarcoma cells. 30 
| Cell culture
A mouse squamous cell carcinoma cell line (Ca3/7) and a mouse skin papilloma cell line (MT1/2) were used for the current studies. The cells were maintained in Joklik MEM supplemented with 8% FBS, 50 U/mL penicillin, 50 ng/mL streptomycin, 10 μg/mL transferrin, 50 μg/mL gentamicin sulfate, 5 μg/mL insulin, 5 ng/mL EGF, 10 μM o-phosphorylethanolamine, and 10 μM 2-aminoethanol. The immortalized human keratinocyte cell line,
HaCaT, 35 were maintained in high glucose DMEM + GlutaMAX supplemented with 10% fetal bovine serum, 50 U/mL penicillin, and 50 ng/mL streptomycin. All cells were grown in an incubator at 5% CO 2 Figure 4A ) and Ca3/7 ( Figure 4B ) cell viability. In order to confirm these findings, we repeated these experiments with another PPARα inhibitor, MK 886, which is less potent than GW6471. Similar effects were observed, as MK 886 significantly increased the IC 50 of UA in both MT1/2 ( Figure 4C ) and Ca3/7
| LDH assay for cell death
( Figure 4D ) cell lines. Overall, these results indicate that UA-mediated cytotoxicity in skin cancer cells is at least partially mediated by PPARα.
| GR did not mediate the cytotoxic effects of UA
A number of studies have shown UA may modulate the GR, which mediates the effects of skin cancer-suppressing glucocorticoids. [28] [29] [30] 34 We found the GR inhibitor RU486, which inhibits both the transactivation and transrepression properties of GR, 39 did not suppress UAmediated decreases in Ca3/7 cell viability ( Figure 5A ). On the contrary, FIGURE 4 UA-mediated decreases in MT1/2 and Ca3/7 viability were blunted by PPARα inhibitors. A, UA-mediated decreases in MT1/2 viability were partially reversed by PPARα inhibitor GW6471 (IC 50 reversal calculated from average of five independent experiments n = 3/ exp, representative experiment shown). B, UA-mediated decreases in Ca3/7 viability were partially reversed by PPARα inhibitor GW6471 (IC 50 reversal calculated from average of six independent experiments n = 3/exp, representative experiment shown). C, UA-mediated decreases in MT1/2 viability were partially reversed by PPARα inhibitor MK 886 (IC 50 reversal calculated from average of four independent experiments, n = 3/exp, representative experiment shown). D, UA-mediated decreases in Ca3/7 viability were partially reversed by PPARα inhibitor MK886 (IC 50 reversal calculated from average of four independent experiments, n = 3/exp, representative experiment shown). For all experiments, *P < 0.05, ***P < 0.005, ****P < 0.001 RU486 significantly enhanced decreases in Ca3/7 viability in response to UA. This indicates that GR activity may mediate a cytoprotective resistance to UA treatment, or RU486 may enhance the effects of UA through a GR activity-independent mechanism.
UA has been demonstrated to have GR-activating properties, and the structure of UA resembles that of typical glucocorticoids. In order to determine if UA functions as a typical glucocorticoid, we performed radioligand binding assays. These assays determine if UA can displace radiolabeled dexamethasone, which should be bound to the traditional 
FIGURE 5
The anti-cancer effects of UA are not mediated by the GR. A, GR inhibitor RU486 enhanced the anti-proliferative effect of UA in Ca3/7 cells (IC 50 values calculated from average of six independent experiments, n = 3/exp, representative experiment shown, *P < 0.05, **P < 0.01). B, UA did not bind the ligand-binding site on GR in HaCaT cells (n = 2, * indicates P < 0.05 between UA and dexamethasone, # indicates P < 0.05 between UA and cortisol, $ indicates P < 0.05 between UA and corticosterone). C, UA did not bind human recombinant GR in a cell-free system (n = 1) dexamethasone from human recombinant GR, while dexamethasone, cortisol, and corticosterone all competed for binding ( Figure 5C ). 45 In addition, our recent studies show that the cytotoxic effects of UA are enhanced with inhibition of p-glycoprotein. 5 In our system, RU486 may decrease the basal expression of p-glycoprotein resulting in increased intracellular UA and enhanced cytotoxicity. 46 
| DISCUSSION

